• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    E

    Edinburgh Cancer Research Centre

    301论文总数
    7,369引用总数

    The Edinburgh Cancer Research Centre (ECRC), also known as the Cancer Research UK Edinburgh Centre and the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.

    论文量&引用量时间轴

    机构学者

    论文(301)

    年份
    起
    –
    止
    排序
    1Bispecific Antibody Against Sclerostin and DKK1 Improves Bone Health and Reduces Bone Marrow Adipose Tissue Accumulation in Experimental Chronic Kidney Disease
    Worachet Promruk,Soher N Jayash, Chartinun Chutoe,Hua Zhu Ke, Xiaofeng Liu, Rachel L Wade, Alexander von Kriegsheim,William P Cawthorn,Katherine A Staines,Louise A Stephen,Colin Farquharson

    Chronic kidney disease (CKD) leads to bone loss and bone marrow adipose tissue (BMAT) accumulation. Sclerostin and dickkopf-1 (DKK1) are two inhibitors of Wnt signalling, which suppress bone formation, promote bone marrow adipogenesis, and are elevated in CKD. However, therapies targeting sclerostin have shown limited efficacy in improving bone health in CKD animal models. Herein, we explored whether dual inhibition of sclerostin and DKK1 via a rodent bispecific antibody (rbsAb) could prevent bone loss and suppress BMAT accumulation in a CKD mouse model. CKD was induced using an adenine-supplemented diet in male mice, with CKD and control mice treated weekly for 6-weeks with vehicle or 30 mg/kg body weight of rbsAb. Circulating sclerostin and DKK1 were ~ 2- and ~ 3-fold higher, respectively, in CKD mice compared to controls. Proteomic profiling by LC-MS/MS and functional enrichment analysis suggested that in CKD mice, adipogenesis, osteoclast differentiation and bone resorption were increased whereas osteoblast differentiation was inhibited. These changes were prevented by antibody treatment. MicroCT revealed that long bones of CKD mice were characterised by lower bone mineral density, trabecular and cortical bone, and impaired biomechanical properties, but their vertebrae were unaffected. RbsAb treatment prevented cortical and trabecular bone loss and restored biomechanical properties. BMAT, as visualised by microCT imaging of osmium-stained bones, was elevated in CKD but reduced to control levels by rbsAb treatment. In conclusion, dual inhibition of sclerostin and DKK1 improved bone integrity and suppressed BMAT in experimental CKD, suggesting a promising therapeutic avenue for renal osteodystrophy.

    2026Bone research(2026)
    引用
    AI阅读
    加入学术空间
    2Combining MAVEs and Computational Predictors Improves Variant Classification Across Ancestries in Hereditary Cancer Genes
    Nikita Bora, Mihaly Badonyi, Ankit K. Pathak, Rutharra Ghayadthri Manisekaran,Joseph A. Marsh,Joanne Ngeow

    Many commonly used computational tools for variant effect prediction exhibit ancestry-related bias because they are trained on clinical or population datasets that under-represent global diversity, leading to uneven and sometimes unfair variant classification across ancestries. Multiplexed assays of variant effect (MAVEs) and population-free VEPs instead offer alternatives that are unbiased with respect to human ancestry, providing classification evidence that generalises across populations. Here, we evaluate MAVE- and VEP-based classification across five cancer-associated genes with high-quality MAVE datasets, focusing on three leading population-free VEPs: GEMME, EVE, and CPT-1. We find that MAVEs are more conservative and decisive in classification, assigning fewer variants to the pathogenic category while yielding fewer indeterminate classifications when calibrated to ACMG/AMP guidelines. While MAVEs show heightened sensitivity in functionally assayed regions, VEPs identify a broader range of pathogenic variants overall. By combining clinical evidence strengths from MAVEs and VEPs, we reclassify over 90% of variants of uncertain significance across the SG10K_Health and Mexico City Prospective Study reference datasets as at least likely benign or likely pathogenic. We further isolate variants where MAVE- and VEP-based classifications are discordant, highlighting method-specific limitations. Together, these findings clarify the complementary strengths of experimental and computational classification approaches and provide a path to less biased and more equitable variant interpretation in clinical genomics, helping to mitigate disparities in diagnosis across ancestries.

    2026Genome Medicine(2026)
    引用
    AI阅读
    加入学术空间
    3Non-Inferiority Margins in Randomized Controlled Trials in Abdominal Surgery – a Systematic Review
    Carl-Stephan Leonhardt, Dominique Birrer, Max F. Stauffer, Johannes Toti,Iain J Gallagher, Richard J. E. Skipworth,Barry Laird,Christoph Kuemmerli

    ABSTRACT Importance Non-inferiority trials are becoming increasingly popular in abdominal surgery. The non-inferiority margin is critical in the interpretation and conclusion of these trials. Objective This systematic review aims to assess the methodological and reporting quality of non-inferiority randomized controlled trials in abdominal surgery. Evidence Review Non-inferiority trials were systematically identified by searching Ovid Medline, Embase and the CENTRAL databases from 2006 until December 2025. Randomized controlled trials in adult patients with any type of abdominal surgical intervention in at least one trial arm and a sample size ≥100 were eligible for inclusion. The primary outcome was the definition of the non-inferiority margin. Secondary outcomes were the reporting of the non-inferiority margin, the robustness of its estimation, the uncertainty of the point estimate and the adequacy of conclusions. Findings A total of 11’045 trials were identified, of which 101 were eligible, enrolling 44’370 patients. Most trials provided a rationale for the non-inferiority design, while six (5.9%) trials did not. Previous literature was commonly used (n=56; 55.4%), but the non-inferiority margin was most often based on a clinical fixed margin or on historical comparison of the treatment and the active comparator. Based on the margin, investigators tolerated substantially worse outcomes of the treatment compared to the comparator. Conclusions were appropriate based on the confidence interval and the predefined non-inferiority margin in 88 (87.1%) of trials. The clinical judgement of the conclusion was overall adequate. Confidence interval estimations were reported in 16 (15.8%) of trials. Simulation studies were limited by the reporting quality. Conclusions and Relevance Clinical fixed margins are commonly used in abdominal surgery non-inferiority randomized controlled trials, however, substantial shortcomings in reporting limit the interpretability and reproduction of study findings. Based on the findings of this study, guidance on surgical-specific non-inferiority margin definitions is needed. KEY POINTS Question How are non-inferiority margins estimated in surgical randomized controlled trials? Findings In this systematic review, non-inferiority margins were nearly always numerically defined, but reporting of how they were estimated was poor. Most frequently, clinical fixed margins were utilized and previous evidence was either ignored or not included at the design stage. The selected margins often tolerated substantially worse outcomes in the treatment group compared to the comparator. Meaning Improved reporting and guidance on the conduct of surgical non-inferiority trials are required.

    2026
    引用
    AI阅读
    加入学术空间
    4Five-year Follow-Up Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab (pembro) for the Treatment of Clear Cell Renal Cell Carcinoma (Ccrcc).
    Naomi Balzer Haas,Thomas Powles,Piotr Tomczak,Se Hoon Park,Balaji Venugopal, Stefan N. Symeonides, Tom Ferguson, Wayne Yen Hwa Chang,Jae Lyun Lee,Piotr Sawrycki,Naveed Sarwar,Howard Gurney,

    4514 Background: KEYNOTE-564 (NCT03142334) established pembro monotherapy as the first adjuvant regimen to significantly improve both disease-free survival (DFS) and overall survival (OS) vs placebo (pbo) after surgery for participants (pts) with ccRCC at increased risk of recurrence. We present results from the fourth prespecified interim analysis with a minimum follow-up of 5 yrs. Methods: KEYNOTE-564 is a randomized, double-blind, pbo-controlled, phase 3 study, which enrolled adults with ccRCC with intermediate-high (pT2 Gr 4 or sarcomatoid, or pT3 any Gr, N0 M0) or high (pT4 any Gr, N0 M0, or any pT and Gr, N+ M0) risk of recurrence or M1 with no evidence of disease (NED) who had nephrectomy and/or metastasectomy ≤12 wks prior to 1:1 randomization to pembro 200 mg or pbo IV Q3W. Treatment continued for ~1 yr (17 cycles) or until recurrence, intolerable AEs, or physician decision to discontinue treatment. The primary endpoint was DFS by investigator; the key secondary endpoint was OS. The study met its DFS and OS objectives at earlier analyses; thus, no subsequent formal statistical testing occurred. AEs were collected for 30-90 days after treatment cessation depending on severity, with serious treatment-related AEs collected regardless of timing. Results: A total of 994 pts were randomized to pembro (n = 496) or pbo (n = 498). The median follow-up time to data cutoff date of 25 Sept 2024 was 69.5 mo (range, 60.2−86.9). All pts completed or discontinued study treatment ≥3 years earlier. 188 DFS events in the pembro group and 241 in the pbo group had occurred. Median DFS was not reached (NR) vs 68.3 mo, respectively (HR 0.71, 95% CI 0.59−0.86); estimated DFS rate at 5 yrs was 60.9% vs 52.2%. 68 OS events in the pembro group and 99 in the pbo group had occurred. Median OS was NR in both arms (HR 0.66, 95% CI 0.48−0.90); estimated OS rate at 5 yrs was 87.7% vs 82.3%, respectively. DFS and OS outcomes were consistent across key subgroups, including by prespecified risk and sarcomatoid features (Table). No new serious treatment-related AEs have been reported for ≥3 years. Conclusions: With ≥5 yrs of follow-up, the benefits observed with adjuvant pembro vs pbo are consistent with prior analyses, including in all subgroups. No new serious treatment-related safety signals occurred. Adjuvant pembro remains a standard-of-care option for patients with ccRCC at increased risk of recurrence. Clinical trial information: NCT03142334 . All pts Prespecified risk subgroups Sarcomatoid features Intermediate-high High M1 NED Present Absent N 994 855 77 57 111 829 DFS events 429 342 49 37 59 339 DFS HR(95% CI) 0.71(0.59−0.86) 0.75 (0.61−0.93) 0.61(0.35−1.08) 0.48(0.25−0.92) 0.56(0.33−0.96) 0.75(0.60−0.92) OS events 167 131 22 13 23 130 OS HR(95% CI) 0.66(0.48−0.90) 0.65(0.46−0.92) 0.86(0.37−1.98) 0.36(0.11−1.18) 0.67(0.29−1.56) 0.64(0.45−0.91)

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)引用:3
    引用
    AI阅读
    加入学术空间
    5Reduced Duration Adjuvant Trastuzumab in the Treatment of Patients with HER2-positive Breast Cancer: a Meta-Analysis of Randomised Controlled Non-Inferiority Trials Including IPD Data.
    Helena M Earl,Louise Hiller, Janet A Dunn, Mubarak Patel,PierFranco Conte,Roberto D'Amico,Valentina Guarneri,Heikki Joensuu,Teppo Huttunen,Dora Hatzidaki,Vassilis Georgoulias, Jean E Abraham,

    Adjuvant trastuzumab in combination with chemotherapy has significantly improved survival in patients with HER2-positive early breast cancer but, since introduction in 2005, the 12 months duration has been questioned and trials have tested shorter durations. A systematic review and meta-analysis using individual patient data (IPD) (when available) from non-inferiority trials of reduced duration trastuzumab was carried out according to PRISMA-IPD guidelines. Primary outcome was invasive disease-free survival (IDFS); secondary outcomes were distant relapse-free survival (DRFS) and overall survival (OS). Estimated survival was calculated using random-effects and fixed-effects modelling, reported by 5 year rates and analysed using non-inferiority methods. Illustrative comparative risks were also tabled as in Cochrane Systematic Reviews. Five trials were identified: PERSEPHONE, PHARE and HORG compared 12 months (m) with 6 m; SOLD and Short-HER compared 12 m with 9 weeks. In the 5-trial analysis (11 389 patients), and in the SOLD and Short-HER (3428 patients) analysis, non-inferiority of the shorter duration was not confirmed. In contrast, for the comparison of 12 m versus 6 m (7961 patients), non-inferiority was confirmed with a 2.5% critical margin, for IDFS, DRFS and OS. The Kaplan-Meier curves demonstrated overlap of credibility intervals throughout follow-up. For every 1000 patients given 6 m trastuzumab, by 5 years, there might be 11 extra IDFS events (in addition to 141 expected for 12 m), 12 more DRFS events (in addition to 106) and nine more deaths (in addition to 73). We have demonstrated that 6 m trastuzumab in early HER2-positive breast cancer is not inferior to 12 m and is an option for patients. CRD42020172267.

    2025BMJ oncology(2025)引用:3
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 301 篇论文

    合作机构(100)

    爱丁堡大学合作论文 67
    西部综合医院合作论文 17
    格拉斯哥大学合作论文 13
    Beatson West of Scotland Cancer Centre合作论文 11
    International Union Against Tuberculosis and Lung Disease合作论文 11
    安大略癌症研究机构合作论文 10
    伯明翰大学合作论文 9
    斯洛伐克科学院合作论文 8
    丹娜—法伯癌症研究所合作论文 8
    德克萨斯大学奥斯汀分校合作论文 8

    机构统计